Behram Mody, MD
Advanced Heart Failure and Transplant Cardiology · Orange, CANPI 1720346240
Payments from drug & device makers
What this record shows
This record is dominated by grants: $11,250 of the $16,501 with a category attached, or 68.2%. Medtronic accounts for 77.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $12,859 and has fallen 91.6% since, to $1,081 in 2025.
Across 50 payments — averaging $330.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$13K
- Edwards Lifesciences$2K
- Abiomed$902
- E.r. Squibb & Sons, L.L.C.$412
- Abbott$382
- Novartis$137
- plus $421 from 5 others
Across 46 payments — averaging $3809.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$90K
- Bayer$85K
What the payments were for
- Grants$11,25068%
- Travel & lodging$2,31714%
- Food & beverage$2,72917%
- Education$2051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $12,709 |
| Edwards Lifesciences | 7 | $1,537 |
| Abiomed | 10 | $902 |
| E.r. Squibb & Sons, L.L.C. | 9 | $412 |
| Abbott | 4 | $382 |
| Novartis | 2 | $137 |
| Ancora Heart, Inc. | 1 | $132 |
| AstraZeneca | 1 | $130 |
| Pfizer | 1 | $128 |
| Philips North America LLC | 1 | $20 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartWare HVAD$11,250
- Impella$533
- CAMZYOS$235
- HeartMate$179
- Ensite Cardiac Mapping System$154
- AccuCinch$132
- VYNDAQEL$128
- LEQVIO$114
How this compares
$16,501 in reported general payments places this provider in the 60th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 208 | $295,265 |
| JardianceEmpagliflozin | 203 | $276,958 |
| EliquisApixaban | 180 | $236,263 |
| CamzyosMavacamten | 23 | $172,520 |
| FarxigaDapagliflozin Propanediol | 35 | $40,056 |
| XareltoRivaroxaban | 19 | $26,327 |
| VascepaIcosapent Ethyl | 13 | $14,046 |
| BrilintaTicagrelor | 13 | $13,203 |
| Metoprolol Succinate | 307 | $4,950 |
| Icosapent Ethyl | 11 | $4,213 |
| Atorvastatin Calcium | 384 | $3,945 |
| Ezetimibe | 89 | $3,198 |
| Rosuvastatin Calcium | 141 | $2,897 |
| Bumetanide | 48 | $2,095 |
| Eplerenone | 33 | $1,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $137 | $295,265208 claims |
| PfizerEliquis | $128 | $236,263180 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $412 | $172,52023 claims |
| AstraZenecaFarxiga, Brilinta | $130 | $53,26048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Orange
- Dawn LombardoOrange$14K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
- Ronald WittelesStanford$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.